RNA-seq analysis of largazole in the brain

Recent studies have demonstrated that HDAC inhibitors show promise as neuroprotectors and considered as potential prospective drug candidates for neurodegenerative and psychiatric diseases. Their beneficial effects have been partly attributed to increased expression of the neurotrophic factors. Largazole, a class I HDAC inhibitor from marine cyanobacteria, could potentially be effective against neurodegenerative and mood disorders. In order to further explore the potential activity of largazole in neurological diseases, applying genomic approaches would aid in the identification of potential genes/targets implicated in those disease settings and being affected by largazole treatment. We applied RNAseq as an approach to quantify changing expression levels in transcripts under largazole treatment.